W La Revue canadienne de psychiatrie, vol 53, no 8, août 2008 496 Objective: To review the problem of chronic pain in patients with substance use disorders, focusing on the prevalence of chronic pain in patients with substance dependence disorders, especially prescription opioid dependence, associated comorbidities, and the impact on drug abuse treatment response.
C hronic pain and substance abuse are independently recognized as complex problems growing in scope and severity. Each has its own unique difficulties that contribute to poor outcomes and partial response to treatment. A substantial and very unfortunate number of patients have both of these devastating problems and constitute a highly stigmatized and plainly underserved population who would benefit from additional scientific and clinical attention. Practical guidance is needed for the assessment, formulation, and treatment of patients with chronic pain and substance dependence disorder. Identifying opportunities and directions for additional research are important elements to advancing our understanding of these problems and their critically important interrelations.
Patients with a partial and poor response to standard treatments for chronic pain are at increased risk of being labelled a drug addict when they request more aggressive pain therapy. Whether they specifically ask for opioid analgesics or not, practitioners will often assume the worst. In patients with known substance use disorder, continuing complaints of pain are routinely regarded simply as drug-seeking behaviour that is undermining their recovery plan. Common approaches to evaluating this complex set of problems often focus on determining whether the patient has a real pain problem or is simply an addict engaged in drug-seeking behaviours. This deliberation has some clear and compelling features; however, the dichotomy is usually oversimplified. The result is an inadvertent underrecognition and undertreatment of chronic pain.
A third situation can arise when patients with unquestionable chronic pain develop an independent substance use disorder despite the most sincere, understandable efforts to seek pain relief. The rush to judgment, often reflected in the evaluation phase, can lead to the emphasis on only one dimension of the presentation (for example, substance abuse or pain) that minimizes the other dimension (pain or substance abuse). One important element in the successful management of these patients who present with features of both problems is tolerating the ambiguity that can dominate the initial evaluation and accepting that the question can be resolved with sufficient time in treatment.
The remaining sections of this article review the background relevant to appreciating the epidemiology of these problems, continuing uncertainties and challenges in the evaluation and treatment of chronic pain and substance use disorder, strategies for the initial management of these patients' treatment while sufficient information is obtained to clarify the extent and severity of these problems and their resulting therapeutic concerns, and concludes with an overview of a promising adaptive evaluation and treatment approach for patients with complaints of chronic pain in the context of known opioid dependence.
Defining Chronic Pain
Chronic pain is an internationally common problem. In the general population, estimates of the point prevalence of chronic pain in the United States range from 10% to ³50%. [1] [2] [3] [4] [5] The prevalence rates observed across these studies reflect variations in the definition of chronic pain. [6] [7] [8] [9] Chronic pain has numerous causes, produces profoundly detrimental effects on physical, psychological, and social functioning, and complicates the evaluation, diagnosis, and treatment of related and unrelated medical and psychiatric disorders. [10] [11] [12] [13] [14] The negative impact of chronic pain on the evaluation and treatment of so many problems unfortunately extends to and is amplified in people with opioid dependence and other drug use disorders.
Important questions remain about how best to define and measure chronic pain. The syndrome is defined using critical cut-off values across relevant domains of duration, intensity, and quality of the pain, combined with the effects of pain on specific areas of physical and psychosocial functioning. 1, [3] [4] [5] Originally, the International Association for the Study of  Pain distinguished chronic pain from acute pain  15,16 by defining it as "pain without apparent biological value that has persisted beyond the normal tissue healing time (usually 3 months)." 15, p 18 Subsequent definitions of chronic pain have proposed variations in the thresholds for duration, intensity, impact on usual functioning, and expanded into other relevant domains of the patients' illness experience (for example, use of rescue analgesics or rates of health care use). 17 Numerous best practice recommendations were made in recent years to guide clinical practice and research on chronic pain. 18, 19 Relevant domains of the experience of chronic pain include assessments of pain intensity and quality, physical and emotional functioning, patient satisfaction and global improvement, and changes specifically attributable to the treatment of pain. In conjunction, the definition of chronic pain used in numerous recent epidemiologic studies and recommended by the World Health Organization now includes the expanded criteria: pain should be present for most of the time during at least 6 consecutive months; moderate-tosevere pain intensity should occur during the course of the episode; and impairment of functioning should be sufficient to warrant discussion of the problem with a health care professional or to motivate use of medication.
dependence and other substance use disorders. Similar to findings in the general population, differences in the definition of chronic pain have contributed to variability in prevalence rates. For example, using a narrow definition that required pain for at least 6 months and moderate or greater intensity, or that significantly interfered with daily activities, Rosenblum et al 21 showed that 37% of patients in methadone treatment programs met criteria for severe chronic pain. A more recent study employed a less conservative definition of chronic pain (requiring 6 months but eliminating the intensity and interference criteria) and reported even higher rates (55%) of chronic pain. 22 Although prevalence rates vary, the low (about 30%) and high end (about 60%) of the range are higher than most general population estimates. [21] [22] [23] [24] [25] [26] [27] While the higher rate of chronic pain in drug-dependent patients is not surprising, it is cause for substantial concern. Chronic pain in other populations is routinely associated with poor psychosocial functioning and quality of life, poor workforce attendance and productivity, increased rates of psychiatric disorders, reduced financial well-being, poor self-rated health, and increased health care use. 3, 9, 14, 28, 29 Available studies suggest that all of these debilitating features associated with chronic pain are similarly present and probably more severe in opioid-dependent patients with chronic pain. Efforts to determine what aspects of chronic pain are most predictive of continued drug abuse as well as psychiatric and physical impairments in drug-dependent populations were hindered by the use of pain measures lacking a comprehensive and multidimensional framework.
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Relation Between Substance Use Disorders and Chronic Pain Conditions
Beginning in the late 1990s, a more than 2-fold increase in lifetime abuse and a nearly 3-fold increase in past-month abuse of prescription opioids occurred in the United States. 33 The Researched Abuse, Diversion and Addiction-Related Surveillance System reported that prescription opioid abuse has become widely prevalent. 34, 35 Increases associated with the abuse of oxycodone and hydrocodone products are particularly alarming. Results from a study of poison control centres found that hydrocodone was the most widely prescribed opioid with the highest rate of intentional exposure (nonmedical use) in the general population. 36 In contrast, rates of intentional exposure for methadone were highest in clinical samples. Increases in methadone diversion and abuse, primarily in tablet form (that is, likely to be prescriptions for pain management rather than take-home dosages from opioid treatment programs) were also reported. 37 This inflection point appeared to coincide with efforts to encourage pain identification and treatment by physicians in conjunction with the marketing of opioid analgesics for the treatment of chronic nonmalignant pain conditions. From 1997 to 2002, the medical use of commonly prescribed opioids markedly increased: morphine 73%, hydromorphone 96%, fentayl 226%, and oxycodone 403%. 38 McCracken et al 39 studied the concerns of patients with chronic pain about medications and their use. Several patterns of nonadherence to or misuse of prescribed medications were characterized. Taking more medication than prescribed was associated with patients' concerns about addiction, tolerance, withdrawal, excessive scrutiny of medication use by others, and a greater perceived need for medication. In a similar study, chronic pain patients with a history of substance abuse were more likely to believe that: narcotic medications are more effective for pain, narcotic use will improve their mood, they would be able to function better with free access to these medications, and they need higher amounts of narcotics to experience pain relief, compared with other patients. 40 Although patients achieved about 50% pain relief and were prescribed similar narcotic dosages, compared with patients without a history of substance abuse, they were significantly more likely to misuse their prescribed medications if they believed they required higher dosages of pain medications than others and their pain control would improve if they had control of the medication. These findings highlight the complexity of managing a patient with both chronic pain and a substance use disorder. Although patients with a history of substance abuse experienced a significant reduction in pain with treatment, there misuse of medications could still be a manifestation of their chronic pain disorder and not simply a reactivation of their addiction.
During the first 5 years after the onset of a chronic pain problem, patients are at increased risk for developing new drug use problems and disorders. 41, 42 The risk was highest among those with a history of drug use disorder or psychiatric comorbidity. [43] [44] [45] [46] [47] Studies also show that opioid-dependent patients with chronic pain have higher rates of drug use than those without chronic pain. 21, 22, 25, 48 For example, chronic pain patients receiving methadone for opioid dependence have higher rates of illicit drug use (such as opioids, benzodiazepines, and cannabis) than patients without chronic pain. A more recent study 49 examined the hypothesis that persistent pain increases the risk of relapse into substance use after detoxification. In a 24-month follow-up study of 397 adults with heroin, alcohol, or cocaine abuse, 54% reported intermittent pain and 16% had persistent pain, both associated with increased use of any substance (OR 4.2), and specifically, opioids (OR 5.4).
Relation Between Prescription Opioid Abuse and Chronic Pain
Little information is known about the characteristics of individuals abusing prescription opioids. Certainly, pain may motivate people to use licit and illicit drugs. 50, 51 For example, 45% of patients in methadone maintenance treatment believed that opioids prescribed for pain led to their addiction. 25 In another study, 31% of patients with controlled-release oxycodone dependence admitted to an inpatient drug abuse treatment facility reported controlled-release oxycodone was initially obtained from a physician for a medical indication such as pain. 52 Another retrospective review assessed prescription opioid abuse by patients entering methadone treatment. 30 In general, prescription opioid-dependent patients were significantly more likely to have a history of or ongoing problems with pain than heroin-dependent patients. Notably, 24% used only prescription opioids (that is, not heroin) and most of them (86%) reported that pain was the reason they began using opioids. Another 24% of the overall sample had used prescription opioids, but subsequently switched to heroin. Among those patients, 62% reported pain as the primary reason for starting to use opioids. Interestingly, data from this study also suggested that the group with prescription opioid abuse had better rates of treatment retention.
Unfortunately, the substance use disorders of chronic pain patients also tend to be severe. Passik et al 53 conducted a prospective survey of chronic pain patients abusing prescription opioid entering a drug abuse treatment facility. Surprisingly, 84% reported legitimately receiving a physician's prescription for pain treatment. However, 91% purchased prescription opioids through illegitimate sources and 80% altered the delivery system of the prescription drug. These studies suggest different circumstances under which individuals arrive at opioid dependence (such as, prior substance abuse, compared with no prior substance abuse, and obtaining the opioid from a physician for a legitimate medical indication, compared with illicit acquisition). Unfortunately, other than a history of substance abuse, the characteristics of patients prescribed opioids initially to treat chronic pain that would reliably predict who will progress to problematic use of the medication are still largely unknown.
Comorbid Psychiatric Conditions in Patients With Chronic Pain and Opioid Dependence
Chronic pain is associated with rates of psychiatric disorder that routinely exceed general population estimates. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] The increased use of prescribed opioids was shown more strongly associated with anxiety and depressive disorders than drug abuse disorders. 66 The complexity of these relations is enhanced by the generally high rates of psychiatric comorbidity detected in opioid-dependent patients in methadone treatment. For example, studies consistently report high rates (³50%) of psychiatric comorbidity in opioid-dependent individuals seeking outpatient methadone treatment. [67] [68] [69] [70] [71] [72] Similar findings were reported in studies on chronic pain conducted in methadone treatment programs. 21, 24, 25 However, these studies did not assess associations between psychiatric comorbidity and chronic pain. The relation between the increased rates of psychiatric problems reported in prior studies of chronic pain in methadone treatment patients and the high rates of psychiatric comorbidity often reported in methadone treatment settings remains unclear.
Effect of Chronic Pain on Response to Drug Abuse Treatment
Chronic pain was shown to negatively affect the course and outcome for an array of medical and psychiatric problems. [73] [74] [75] Similar findings were reported in studies of opioid-dependent patients receiving outpatient drug abuse treatment with methadone and counselling. Conceptually, there are at least several ways that chronic pain could alter and interfere with the response to drug abuse treatment: chronic pain could increase illicit drug-seeking motivation and drug-taking behaviour to reduce pain symptoms; chronic pain could increase the motivation to use illicit drugs that produce euphoria to improve subjective well-being and quality of life of these already demoralized patients; chronic pain symptoms and impairment are associated with the presence of other psychiatric disorders, many of which were shown to decrease response to drug abuse treatment; and chronic pain is often associated with disability that reduces psychosocial activity and subsequently hinders seeking or sustaining employment or attending drug abuse treatment sessions, common problems independently associated with reduced drug abuse treatment response (see Currie et al, 76 Fuller et al, 77 Kidorf and Brooner, 78 Kidorf et al, [79] [80] [81] [82] Trafton et al, 48 Weaver and Schnoll
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Psychiatric and medical disorders in patients with substance abuse were shown to predict poorer outcomes to drug abuse treatment. While studies generally report much higher rates of drug use, psychiatric problems, and functional impairments in patients with opioid dependence complicated by chronic pain, associations between chronic pain and response to outpatient methadone treatment were inconsistently reported in a small group of studies. 83, 84 For example, Peles et al 22 showed that opioid-dependent patients in methadone maintenance therapy, who reported chronic and severe pain, submitted a greater proportion of sedative-positive urine specimens than those without chronic pain. A similar study found that opioid-dependent patients with chronic pain in drug abuse treatment including methadone maintenance 24 However, patients with pain remained significantly more impaired in other domains of physical and psychosocial functioning. A comparable study examined the outcome of long-term methadone treatment for chronic pain and problematic opioid use patients. 85 Good pain relief was achieved by 75% of patients on an average methadone dosage of 82 mg/day. Quality of life and function significantly improved; however, the study was limited by a small sample size, high drop-out rates, and severe adverse events. The authors concluded that long-term methadone for chronic pain is a complex treatment process that should involve a multidisciplinary team with "meticulous follow-up." 85, p 277 Unfortunately, most of these studies provide little information on the scope of treatment services offered to patients (such as, number of individual and group counselling sessions, and urine testing schedules and procedures), and even less information on the amount of treatment services they actually received and how the treatment influenced the course of chronic pain.
Ideally, substance abuse treatment should use a highly structured, adaptive, stepped care approach with behavioural incentives to motivate patient adherence. [86] [87] [88] Many services constituting routine substance abuse treatment in a program with well-described outcomes, including the use of coping skills training, significant other support, and incentives to increase patient adherence, are recognized as important aspects of good rehabilitative care for all people with chronic health problems, including chronic pain syndromes. [89] [90] [91] [92] [93] [94] [95] [96] These features of effective substance abuse therapy could indirectly benefit chronic pain because of an increase in general function attributable to learning new skills coupled with abstinence from drug use.
However, substance abuse treatment may directly decrease chronic pain. For example, methadone may also provide patients with analgesic benefits. In a study of opioiddependent patients, those with severe chronic pain received higher dosages of methadone, compared with those without chronic pain. 22 While higher dosages may reflect attempts to treat pain, indicators of substance abuse treatment outcomes were worse for this group, suggesting a more severe substance abuse disorder. The relations between chronic pain and treatment of substance use disorders still need clarification.
Assessment of Chronic Pain in Opioid-Dependent Patients
The obvious risks of patients misusing or abusing analgesic medications in the context of opioid and other drug dependence disorders is clearly mitigated, to some extent, by the substantial risks of undertreating pain. The undertreatment of pain was reported as disproportionately more problematic in patients with substance use disorders, including those receiving long-term methadone maintenance therapy. 27, 97 Most experts agree, the systematic undertreatment of chronic pain can inadvertently increase drug use and the overall severity of a drug dependence disorder. 48, [98] [99] [100] However, detecting and evaluating the misuse of prescribed opioids in patients with chronic pain and an opioid or other substance use disorder remains a challenge. 45, [101] [102] [103] Practitioners struggle with the diagnosis of drug dependence (that is, addiction) in patients receiving opioids for pain management. Regardless of chronic pain presence or prescribed opioid treatment, patients with substance use disorders still manifest the same criteria of their disorder: loss of control over drug use; compulsive drug use; and continued drug use despite harm, including deteriorations in function. 104, 105 While aberrant medication-taking behaviours are not uncommon in chronic pain patients, all patients need ongoing assessment about how any aspect of their condition and its treatment is affecting their functioning. 106, 107 If function is stable and productive, then the problems are likely addressed and treatment is probably safe and effective. If function is deteriorating, then the cause (such as, addiction, cognitive impairment, psychiatric disorder, diversion, worsening pain, and medical problems) must be sought and defined so that specific modifications to the treatment plan can be implemented. This pragmatic approach to patient care in real time helps resolve continuing philosophical debates over concepts of beneficence, nonmalfeasance, therapeutic dependence, pseudoaddiction, and subtle withdrawal phenomena.
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The question is not if patients with substance use disorder and chronic pain should ever be treated with opioids but how the medication should be used when the need arises.
Treatment of Chronic Pain With Opioids in Opioid-Dependent Patients
Long-term opioid use for the treatment of chronic pain remains controversial and may be complicated by numerous adverse outcomes. 110, 111 Numerous guidelines were established for the treatment of chronic nonmalignant pain with opioids. 111 All versions attempt to codify the common sense principles embodied in careful assessment and close follow-up: opioid therapy has risks, some of these risks are greater in individuals with substance use problems, nonopioid modalities of pain treatment should be emphasized (such as, medications, cognitivebehavioural psychotherapy, physical therapy, interventions such as nerve blocks, epidural steroids, and complementaryalternative medicine); second opinions and consults should be regularly obtained; sustained-release opioid preparations are preferred over short-acting ones; and the goals of treatment should be closely monitored with a focus on pain relief and improved function while minimizing drug-related adverse events and aberrant drug-taking behaviours. 51 Scimeca et al 27 reviewed the principles of treating pain in patients receiving methadone maintenance. Similarly, their approach emphasized the need for a careful assessment with detailed evaluation of pain and all comorbidities, appropriate analgesia with other mu agonists added to methadone, and close monitoring with a team of professionals.
An interesting study of opioid treatment investigated aberrant drug-related behaviours in patients with HIV-related pain and a history of substance abuse, compared with patients with cancer pain and no history of substance abuse. 114 The HIV patients reported more than twice as many aberrant drug-related behaviours. Inadequate pain relief from prescribed analgesic therapy was associated with the following actions: raising the dosage of opioids on one's own, telling family members that they would use street drugs to relieve pain, using more opioids than the physician recommended, and using opioids to treat other symptoms. Aberrant drugtaking behaviours were predicted better by demographics, drug abuse history, and psychological distress than by pain-related variables. Therefore, the emphasis in treatment should be on behaviour and function, past and present. While pain relief is an important outcome, the deterioration in a patient's function and the emergence of aberrant drug-taking behaviours are red flags for providing more intensive treatment. Although it is likely the need is for more intensive substance abuse treatment, reexamining the patient's pain treatment plan should also be performed.
As noted, one of the more important aspects of successful management of patients with both chronic pain and substance use disorder is avoiding the trap of deciding whether pain complaints are real or a manifestation of drug-seeking. This trap leads to a premature and uninformed guess about the need to focus treatment on either pain or substance abuse. The initial assumption is simple. Their pain complaints are real and not a substance abuse manifestation but a request for treatment. Until what treatment forms should be used are clear, treatment should address both problems simultaneously (Figure 1) . Patients should be initiated into therapy with a comprehensive evaluation of the characteristics and severity of their specific problems. If more than one problem exists, a multidisciplinary treatment plan should be formulated. The patient's ongoing response to treatment for each problem should be assessed frequently. The problem-specific outcome measures should then guide the degree to which each problem receives more intensive therapy. Despite best intentions, this approach usually devolves to an excessive focus on one problem coupled with an inadequate focus on the other problem. First, it is crucial to remember that patients with both disorders require ongoing careful evaluation for both. Second, an ongoing discussion with patients and family about their response to treatment should occur regularly. Finally, how the continuing plan of care will be modified should be clear to all parties. These basic principles of treatment form the foundation of a program designed to motivate patients in treatment and adapt to individual needs to insure successful outcomes.
Enhancing Treatment: New Recommendations for Integrated Approaches
The common interactions between chronic pain, opioids, and other drug use problems, and other medical and psychiatric problems, makes treatment-seeking, opioid-dependent patients a critically important subgroup of patients with a compelling need for enhanced evaluation and treatment services. [98] [99] [100] Regrettably, patients with chronic pain and substance use disorder (especially opioid dependence) remain a largely stigmatized, maligned, and often neglected population. 21, 23 This clinical and public health mismatch likely increases the risk for drug-seeking behaviour in these patients, including self-medication with illicit drugs and the serious associated hazards.
While substance abuse treatment is generically recommended, there is little discussion about how routine substance abuse treatment can accommodate the needs of a patient with a comorbid chronic pain syndrome. The level of difficulty associated with managing these patients is increased by the infrequent assessment typical of routine chronic pain and drug abuse treatment programs, in addition to their often inaccurate and underreported prescription medication and illicit drug use. 115, 116 Some of these problems would be reduced if routine treatment was modified to: incorporate ongoing detailed assessments that begin with an extensive history of prior pain and drug use problems; provide for testing of weekly urine specimens for opioids (prescribed and illicit) and other drugs; and offer appropriate positive reinforcements for reporting the use of opioids prescribed by other practitioners to account for the detection of these potentially illicit substances in their urine specimens.
Interestingly, most research and clinical recommendations discuss how to use opioids for the treatment of pain in people with substance use disorders. There is comparatively little discussion about whether other modalities of therapy may be more effective, safe, and appropriate. The assumption that opioids are first-line therapy in this population further stigmatizes these patients by implying that a comprehensive evaluation and treatment plan usually provided to patients without substance use disorders should only be implemented as a last resort for patients with both drug abuse and chronic pain. This recommendation simply accepts that patients with substance use disorder do not have access to high-quality medical care and reinforces the belief that they do not deserve it or that they would reject any alternative to opioid-based treatments.
For example, only brief mention is made of nonopioid medications for the treatment of neuropathic pain problems, interventional approaches for reducing musculoskeletal pain, and active physical therapies for enhancing efforts of rehabilitation. Multidisciplinary pain treatment programs have not been incorporated into substance abuse treatment programs, which are not staffed to provide pain evaluation and management. Multidisciplinary pain treatment programs usually seek to avoid patients with clear opioid dependence. The so-called hot potato patient with both problems receives inadequate or no treatment thereby decreasing any chance for improvement and success.
A recent report from an ongoing randomized trial is already showing that integrating specialized psychiatric treatment services (pharmacotherapies and psychotherapies) in a substance abuse treatment setting is associated with significant improvement in the number of people receiving care, amounts of service received, psychiatric symptoms, weekly urine test results, and self-report ratings of response to treatment. 117, 118 This pattern of findings was also shown in studies integrating a limited number of primary care or obstetric services into drug abuse treatment settings.
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The rationale is strong for assuming that similar success would be achieved from the integration of on-site evaluation and treatment of chronic pain into large substance abuse treatment settings managing people with opioid dependence.
A study of patients with both chronic pain and substance use disorder showed that a 10-week outpatient group therapy for pain management integrated with a multidisciplinary substance abuse treatment program was associated with a reduction in pain and emotional distress, improvement in coping skills, and a reduction in the use of pain medications including opioids. 76 The expertise of multidisciplinary pain management has largely been denied to substance use disorder patients. Offering these patients more opioids may provide some benefits yet to be determined; however, improving access to adjuvant analgesics, nonpharmacologic treatments, and structured rehabilitative programs with well-documented efficacy should be a priority. At least some of these patients are not seeking opioids merely for their intoxicating effects. An appropriate starting point assumes that patients are seeking relief from chronic pain and have little to no access or knowledge about nonopioid modalities that are clearly less controversial, less potentially destabilizing of their addiction, and likely to be more effective at decreasing pain.
One promising approach for an integrated treatment program for chronic pain and substance use disorder involves an adaptive stepped care strategy initially designed for routine substance abuse treatment (Figure 2) . [86] [87] [88] The basic principle of this model of care relies on providing more services for patients not meeting the expectations of treatment. In other words, patients enter treatment at a level of care that provides standard individual and group counselling, daily supervised methadone dosing, and urine screening for illicit drug use. As the patient continues in treatment, additional expectations for improved function, such as productive activities in the community (such as, employment, training, and volunteering), increased relationships with others not using drugs, and structured diversional activities, are required to remain in this routine or low-intensity level of care (Step 1). If the patient does well, their progress is reinforced with a less intensive schedule of counselling services, more flexibility in the time of methadone dosing, and increased take-home dosages of methadone to reduce clinic visits. Patients are motivated by the obvious positive reinforcements of methadone itself and the freedoms that result with adherence to the behavioural treatment plan. In addition, patients are further motivated to improve their compliance with treatment by their own desire to avoid being placed in more intensive treatment with even higher expectations and the loss of desired privileges.
The determination to advance a patient to more intensive treatment or a higher step of care is based on established a priori rules that use the results of attendance and urine testing.
As patients begin to demonstrate poor adherence to these expectations, the program adapts to that patient's individual needs. The practitioner assumes that the patient's disorder is more complex and requires more intensive treatment. Instead of being discharged from treatment because they are not ready to get well or just trying to gain unlimited access to opioids, the patient is advanced to a higher level of care with access to more experienced senior staff, more frequent group therapy sessions, more individual counselling sessions, more closely monitored methadone administration, and more frequent illicit drug use monitoring. If patients do not respond within a predetermined time frame, they are advanced to higher steps of care. When patients begin responding to therapy (attend counselling sessions, decrease use of illicit drugs), they return to less intensive treatment schedules. As noted, increased adherence is motivated by their pursuit of desired or previously obtained positive reinforcements such as take-home dosages of methadone and the opportunity to achieve or return to less restrictive schedules of care. Patients with both chronic pain and substance dependence appear to be excellent candidates for an adaptive stepped care approach with only minimal modifications from the approach used to manage substance use disorder not complicated by chronic pain ( Figure 3) ; these modifications are outlined below.
Recognize the Associations Between Chronic Pain and Substance Use Disorder. Inadequately treated pain is recognized as a cause of poor adherence and response to substance abuse treatment. Screening patients with standardized questionnaires for the presence of pain and its associated characteristics (such as, intensity, unpleasantness, location, and duration) is the first step ( Figure 1 ). In addition to the characteristics of pain, patients should be evaluated for the impact that pain has on daily functioning and quality of life. This information should then be reevaluated during the course and follow-up of the patient in substance abuse treatment. Pain-specific treatments should be initiated as soon as a chronic pain disorder is discovered instead of waiting until the patient has a poor response to substance abuse treatment.
Expect Pain to Complicate Substance Abuse Treatment.
Similar to other untreated medical and psychiatric problems, chronic pain is expected to interfere with the clinical course and outcome of substance abuse treatment. Therefore, either complaints of pain or signs of poor adherence should result in more aggressive diagnostic evaluation and implementation of pain management strategies (steps) that occur simultaneously with increased levels of drug abuse treatment. However, if the problems worsen or improve independently from one another, the steps of care can be disconnected. In other words, a patient might continue in high-intensity (Step 3) treatment for substance abuse but drop back to low-intensity (Step 1) treatment for pain management. The patient, not the practitioner, determines the priority list of problems through their response to treatment. The treatment adapts to the objectively demonstrated needs of the patient and is independent from the worries or prejudices of the practitioners.
A key principle for designing a stepped care program rests on the fact that a higher step with more intensive treatment must still offer to the patient an achievable set of changes to the treatment plan. If the increased expectations of the patient are too demanding with no potential for success, the patient will become demoralized and leave treatment. Also, the step's efficacy must be assessed for all patients to determine if its content is adequate or whether additional steps of even more intensive treatment are required. When in place, the adaptive treatment program offers a plan for patients who are not doing well. However, the adaptive treatment program should also be refined over time. The number of steps and their treatment content should be based on the program's ability to successfully address the most complex patients' needs.
Maximize the Benefits of Methadone. In addition to the behavioural reinforcements that motivate patients in treatment previously discussed, methadone can be used effectively for the treatment of both chronic pain and substance use disorders. If the patient is not responding well to treatment, not only can the methadone dose be increased but the dosing schedule can be split. Because methadone's analgesic properties last only about 6 hours, a split dosage schedule may extend the hours throughout the day that a patient experiences increased analgesia. This may initially be difficult for the patient because they would have to return to the clinic twice a day to receive the additional methadone dose based on the requirements of their substance abuse treatment. Step 2
• Modify pain management
Step 1
• Add pain management
Step 3 patient is able to abstain from illicit drug use, they can initially earn this second (one-half) dose as a take-home. Eventually, as patients stabilize in treatment and receive full take-home doses of methadone, they can split their own dose with the potential of following up to a Q6-hour schedule.
Introduce Nonopioid Therapies Early. The use of nonopioid therapies for chronic pain is inexcusably rare. These highly effective modalities should be introduced early in therapy and not as a last resort when opioid medications have failed. The patient with chronic pain should receive education and group therapy about the efficacy of nonopioid medications and nonpharmacological modalities of managing chronic pain. Stress management, coping skills training, relaxationbiofeedback techniques, and physical therapies directed at reducing chronic pain and improving function should be used.
Higher steps of pain management should offer more individual sessions to understand and address the problems likely to be more specific to the refractory patient.
Medications such as antidepressants and anticonvulsants used to treat neuropathic pain should be prescribed. If necessary, the dosing of these medications can be monitored in conjunction with their methadone. They can be administered by observant program staff to ensure the medication is taken as prescribed. Serum levels may be obtained to monitor compliance as well as adjust dosing schedules. As previously noted, treatment is not contingent solely on compliance to counselling sessions and abstinence from illicit drug use but reinforced through the delivery of methadone and other medications to minimize noxious symptoms and prevent illicit drug effects, the patient's desire to avoid more intensive levels of care that the patient may believe are more restrictive, and the pursuit of the rewards associated with lower steps of care that accompany adherence, which is defined as a decrease in illicit drug use coupled with increases in functioning (such as, attendance and employment).
Conclusions and Future Research
There is a growing consensus that the prevalence of cooccurring chronic pain and substance use disorders is high and presents a significant burden to the health care system and society. Treatment approaches that target either one of these problems run the risk of ignoring the other and compromising the overall care and prognosis of these patients. Cartesian dualism in any form is an inadequate model for the assessment, formulation, and treatment of patients. These patients cannot be clearly understood from an either-or perspective. Attributions of all of the patients' symptoms to either chronic pain or substance use disorder often fail to appreciate the complex relations between these problems. In combination with limited access to integrated treatment programs and settings, the outcome for many of these patients is grim. Future research is necessary to help guide progress. Studies that provide much more comprehensive evaluation of both problems and prospective characterization of chronic pain problems in opioid-dependent patients seeking outpatient methadone treatment would be most helpful. Equally important, interventions for chronic pain to improve response to drug abuse treatment are needed.
These new efforts should expand existing expertise in the assessment of psychiatric comorbidity and integrated treatment delivery models into the domain of chronic pain, which is clearly an underdiagnosed and poorly treated medical and psychiatric problem in substance use disorder patients. Increasing nonopioid medication use, typically used to treat chronic neuropathic pain conditions such as antidepressants and anticonvulsants that are underused in general medical care and rarely prescribed to substance use disorder patients, should become a priority. 21 Improving access to comprehensive pain treatment programs would offer more hope to patients with chronic pain and substance abuse than continuing to advocate for the use of unimodal therapies such as long-term opioid agonists. 27, 121 Implementing and evaluating the principles of rehabilitation used by multidisciplinary pain centres and selected substance abuse treatment programs would deepen our understanding of the associations between chronic pain and response to highly structured adaptive drug abuse treatment settings. These data would improve outcomes and provide a strengthened empirical foundation for the design and implementation of clinical trials to reduce the suffering and impairment associated with chronic pain in people with chronic and severe opioid dependence. The results would likely generalize to other chronic pain patient populations to improve our understanding of the risks of opioid treatments, and hopefully prevent the development of opioid dependence in at least some of these high-risk individuals.
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Résumé : Évaluation et prise en charge de la douleur chronique chez les personnes cherchant un traitement pour le trouble de dépendance aux opiacés Objectif : Examiner le problème de la douleur chronique chez les patients souffrant de troubles d'utilisation de substances, en mettant l'accent sur la prévalence de la douleur chronique chez les patients souffrant de troubles de dépendance aux substances, en particulier de dépendance aux opiacés sur ordonnance, les comorbidités associées, et l'effet sur la réponse au traitement de l'abus de drogues.
Méthode : Nous avons relevé les articles pertinents à l'aide de PubMed, de 1987 à 2008. Les articles additionnels ont été obtenus à même les bibliographies des études clés de sujets pertinents. Les études étaient incluses si elles exploraient la relation entre la douleur chronique et les troubles d'utilisation de substances. Les articles qui proposaient un traitement intégré des deux problèmes revêtaient un intérêt particulier.
Résultats : La prévalence élevée des syndromes de douleur chronique n'a été explorée que récemment chez les patients cherchant un traitement pour abus de drogues. La présence de la douleur chronique accroît le risque d'une réponse médiocre au traitement de l'abus de substances et accroît aussi la probabilité de comorbidités multiples qui ajoutent encore aux répercussions négatives que connaissent les patients souffrant de troubles de dépendance aux substances. Les programmes de traitement de l'abus de substances offrant des soins médicaux et psychiatriques intégrés pour ces comorbidités ont de meilleurs résultats, et les approches de soins par paliers offrent le meilleur traitement en personnalisant le niveau des soins selon les besoins individuels du patient.
Conclusions : Les programmes de traitement de l'abus de substances devraient développer leurs services pour aborder les comorbidités aptes à faire obstacle à un rétablissement réussi de l'usage de drogues. Étant donné la prévalence élevée et les répercussions négatives de la douleur chronique, de nouveaux services de soulagement de la douleur devraient être intégrés au programme de traitement de l'abus de drogues, et adaptés à mesure que les patients démontrent le besoin d'un traitement plus intensif. Si on l'applique au problème de la douleur chronique, un programme modèle de traitement de l'abus de substances comportant des soins par paliers intégrés améliorerait les résultats pour les patients souffrant des deux troubles dévastateurs.
